Boehringer Ingelheim and Lilly highlight positive new Jardiance data

Boehringer Ingelheim and Lilly have announced data from two phase III clinical trials that further underline the safety and efficacy of their recently-approved type 2 diabetes drug Jardiance.

Results shared at the American Diabetes Association scientific sessions have demonstrated that the empagliflozin-based sodium glucose cotransporter 2 inhibitor therapy was able to significantly reduce blood glucose and body weight when used as an add-on treatment.

When added to metformin, Jardiance was associated with greater reductions in both metrics versus glimepiride in a two-year study. Meanwhile, when added to multiple daily insulin injections in obese adults on high insulin doses, the drug significantly reduced blood glucose and body weight with lower insulin doses compared to placebo.

Professor Klaus Dugi, chief medical officer at Boehringer Ingelheim, said: "The encouraging results from these trials show that empagliflozin taken in combination with either metformin, or with multiple daily injections of insulin, reduced blood glucose levels and body weight."

Jardiance was approved by the European Commission as a means of improving glycaemic control in adults affected by type 2 diabetes in May 2014.